Xanthurenic acid derivative pharmaceutical compositions and methods related thereto

Abstract

The present invention relates to diuretic pharmaceutical compositions and methods and in particular to certain derivatives of the formula I: or a prodrug or pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier.

1 .- 24 . (canceled) 
     
     
         25 . An isolated antibody that specifically binds to xanthurenic acid-8-O-β-D-glucoside. 
     
     
         26 . The antibody of  claim 25  which is a monoclonal antibody. 
     
     
         27 . The antibody of  claim 25  which is a polyclonal antibody. 
     
     
         28 . A diagnostic kit for assaying xanthurenic acid-8-O-β-D-glucoside in a serum sample, comprising one or more monoclonal antibodies directed against xanthurenic acid-8-O-β-D-glucoside. 
     
     
         29 . (canceled) 
     
     
         30 . A process for monitoring or detecting a disease associated with an abnormal level of xanthurenic acid-8-O-β-D-glucoside; the process comprising:
 a. exposing a biological sample to a monoclonal antibody directed against xanthurenic acid-8-β-D-glucoside; and 
 b. detecting a level of xanthurenic acid-8-β-D-glucoside in said biological sample using the monoclonal antibody, wherein an elevated level of xanthurenic acid-8-O-β-D-glucoside in said biological sample is associated with the disease. 
 
     
     
         31 . The process of  claim 30 , wherein said disease is selected from the group consisting of hypertension, edema, acute renal failure, congestive heart failure, chronic renal failure, ascites, increased intra-ocular pressure, nephrotic syndrome or other disease state involving irregularities in fluid/sodium balance. 
     
     
         32 . The process of  claim 30 , wherein said biological sample is a urine sample. 
     
     
         33 . The process of  claim 30 , wherein said biological sample is a serum sample. 
     
     
         34 .- 37 . (canceled)